Novo Nordisk
2012-04-17T17:27:02Z
2012-04-17T17:27:02Z
Novo Nordisk A/S: US Supreme Court ruling allows Caraco Pharmaceutical to challenge Novo Nordisk's patent submissions for Prandin® (repaglinide)
Today, Novo Nordisk announced that the US Supreme Court has reversed the US Court of Appeals for the Federal Circuit's April 2010 decision. That decision dismissed generic manufacturer Caraco Pharmaceutical's claim to change Novo Nordisk's patent submissions regarding the combination use of repaglinide and metformin for the treatment of type 2 diabetes.
Further information:
| Media: | Investors: |
| Mike Rulis | Klaus Bülow Davidsen |
| Tel: (+45) 3079 3573 | Tel: (+45) 4442 3176 |
| mike@novonordisk.com | klda@novonordisk.com |
| Frank Daniel Mersebach | |
| Tel: (+45) 4442 0604 | |
| fdni@novonordisk.com | |
| Lars Borup Jacobsen | |
| Tel: (+45) 3075 3479 | |
| lbpj@novonordisk.com | |
| In North America: | |
| Ken Inchausti | Jannick Lindegaard |
| Tel: (+1) 609 514 8316 | Tel: (+1) 609 786 4575 |
| kiau@novonordisk.com | jlis@novonordisk.com |
Company Announcement No 25 / 2012